SHARPIN

Across TCGA pan-cancer cohorts, SHARPIN mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SHARPIN data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SHARPIN mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SHARPIN expression acts as an unfavorable survival marker.

CCRCC, LUAD, and PDAC are the cancer types where SHARPIN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.825	0.966	.016	16	view →
LUAD	DFS	Median	All	0.486	0.705	.033	6	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SHARPIN–CCRCC (OS)

Open the CCRCC breakdown →